Drug intelligence / Profile preview

menotrophin (Ningbo Renjian Pharmaceutical)

Development stage
Unknown
Lead developer
Ningbo Renjian Pharmaceutical Group
Administration
Intramuscular, Subcutaneous
01

Overview

Human Menotrophin for Injection (HMG) is a biological hormone product developed and manufactured by Ningbo Renjian Pharmaceutical Group. It contains menotrophin, a gonadotropin extracted from the urine of postmenopausal women, which consists of a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The drug acts as an agonist at the FSH and LH receptors in the ovaries, stimulating follicular growth, maturation, and the production of gonadal steroids. It is approved in China for the treatment of female infertility, specifically for primary or secondary amenorrhea and anovulation caused by gonadotropin deficiency. The product is supplied as a lyophilized powder for injection in 75 IU and 150 IU specifications.

Brand names
Human Menotrophin for Injection
Other names
human menopausal gonadotropin
02

Targets

FSHR (Follicle-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)

Beyond the preview

Go deeper on menotrophin (Ningbo Renjian Pharmaceutical).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on menotrophin (Ningbo Renjian Pharmaceutical).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call